Hypophysitis is a notable risk in immunotherapy, often manifesting as fatigue, headache, or visual disturbances roughly 12 weeks into therapy. Available Formats
Newer immune-checkpoint inhibitors (ICIs) require specialized causality assessment scales like RECAM to distinguish drug-induced injury from other causes. : Toxicidades
The ( Common Terminology Criteria for Adverse Events ) is the standard tool used to grade these toxicities. Gastrointestinal and Liver Toxicity : Hypophysitis is a notable risk in immunotherapy, often
: Includes detailed protocols for chemotherapy, immunotherapy, targeted therapies, and radiotherapy . often manifesting as fatigue
This manual specifically addresses the complexities of modern cancer treatments, moving beyond conventional chemotherapy to include cutting-edge therapies.